FUNCTION OF CALCITONIN RECEPTORS
降钙素受体的功能
基本信息
- 批准号:6100313
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-01-01 至 1998-12-31
- 项目状态:已结题
- 来源:
- 关键词:G protein arthritis autoradiography calcitonin hormone receptor immunocytochemistry in situ hybridization laboratory mouse laboratory rat molecular cloning northern blottings organ culture pathologic bone resorption phosphorylation protein isoforms protein structure function radioimmunoassay receptor binding receptor coupling receptor expression site directed mutagenesis
项目摘要
The recent cloning of porcine, human and murine calcitonin receptors
(CTRs) by our laboratory and analysis of their structural features
indicates that they belong to a new family of G protein-coupled receptors
that includes the receptors for several members of the secretin/glucagon
peptide family and parathyroid hormone/parathyroid hormone related
peptide. The CTR cDNAs have provided us with experimental tools to
define the molecular basis for the broad spectrum of biological and
pharmacological effects of calcitonin (CT) and for determining the
mechanisms underlying the observed cross-reactivity of CT with related
ligands. The basis for the unique functional properties of the CTR,
including the capacity to couple to multiple signal transduction pathways
and to produce sustained activation of adenylate cyclase can also be
explored. Initial studies indicate the presence of CTR isoforms and
possibly subtypes with distinct functional properties. These findings
provide the basis for Specific Aim 1 which is to clone and characterize
the structural and functional properties of different CTR isoforms and
related receptors. The observed structural and functional heterogeneity
that we have detected among the CTR cDNAs that we have already cloned
could proved the basis for tissue-specific regulation of responses to CT
and related peptides. Specific Aim 2 will use in situ hybridization with
probes prepared from the CTR clones and immunohistochemistry with
antibodies to the CTR, to establish the tissue distribution of these
receptors. Because the CTR family of receptors exhibits structural
features that are different from the other members of the G protein-
coupled receptor super family, the structure/function relationships for
these additional clone CTR cDNAs, to define the structural determinants
underlying the unique functional properties of the CTR. Specific Aim 3
proposes to use techniques of site-directed mutagenesis and construction
of chimeric receptors to define the structural domains associated with
ligand binding and coupling to G proteins associated with activation of
specific signaling pathways. The development of refractoriness
("escape") to the hypocalcemic effects of CT is a significant problem in
the clinical and therapeutic use of CT. Insights into the mechanisms
underlying this condition should lead to more effective use of CT in the
treatment of disorders of skeletal remodeling. The goal of Specific Aim
4 will be to define the molecular and cellular basis of this state of
refractoriness to CT and to establish its relationship to the processes
of receptor desensitization and down-regulation.
猪、人和鼠降钙素受体的克隆
(CTR)的结构特征进行了分析
表明它们属于一个新的G蛋白偶联受体家族
包括胰泌素/胰高血糖素几个成员的受体
肽家族与甲状旁腺激素/甲状旁腺激素相关
肽。 CTR cDNA为我们提供了实验工具,
定义了广谱生物学和
降钙素(CT)的药理学作用,并确定
观察到的CT与相关的
配体。 CTR独特功能特性的基础,
包括与多个信号转导途径偶联的能力
并产生腺苷酸环化酶的持续激活,
探讨了 初步研究表明CTR亚型的存在,
可能是具有不同功能特性的亚型。 这些发现
为具体目标1提供基础,具体目标1是克隆和表征
不同CTR同种型的结构和功能特性,
相关受体 观察到的结构和功能异质性
我们在已经克隆的CTR cDNA中检测到的
可以证明组织特异性调节对CT的反应的基础
和相关肽。 Specific Aim 2将使用原位杂交技术,
从CTR克隆制备的探针和免疫组织化学,
CTR的抗体,以建立这些抗体的组织分布。
受体。 因为CTR受体家族表现出结构上的
与G蛋白其他成员不同的特征
偶联受体超家族,结构/功能关系,
这些额外的克隆CTR cDNA,以定义结构决定簇,
这是CTR独特功能特性的基础。 具体目标3
建议使用定点诱变和构建技术
嵌合受体的结构域,以确定与
与G蛋白的配体结合和偶联,
特定的信号通路。 耐火材料的发展
(“逃避”)CT的低钙效应是一个重要的问题,
CT的临床和治疗应用。 深入了解机制
这种情况的基础应该导致更有效地使用CT在
治疗骨骼重塑疾病。 具体目标的目标
4将是定义这种状态的分子和细胞基础,
CT的不应性,并建立其与过程的关系
受体脱敏和下调的过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN GOLDRING其他文献
STEVEN GOLDRING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN GOLDRING', 18)}}的其他基金
ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
- 批准号:
10326409 - 财政年份:2020
- 资助金额:
-- - 项目类别:
ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
- 批准号:
10013068 - 财政年份:2020
- 资助金额:
-- - 项目类别:
ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
- 批准号:
10281291 - 财政年份:2020
- 资助金额:
-- - 项目类别:
GORDON CONFERENCE ON CELL AND MOLECULAR BIOLOGY OF BONES
骨骼细胞和分子生物学戈登会议
- 批准号:
2083284 - 财政年份:1995
- 资助金额:
-- - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
-- - 项目类别: